Clinical trials: Malignant Peritoneal Effusion, open to volunteers
Malignant Ascites Caused by Advanced Solid Tumors
A Clinical Study of GK02 in Malignant Ascites
A single-arm, single-center, open-label clinical study comprising three cohorts, evaluating the safety, preliminary efficacy, and pharmacokinetic/ pharmacodynamic (PK/PD) characteristics of autologous tumor-reactive T cells…
- Trial name
- NCT07378436
- Testing
- GK02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Geekgene Technology Co., LTD
Malignant Ascites
At-Home Paracentesis for Cancer-Related Malignant Ascites (Paracentesis)
The goal of this study is to evaluate the change in symptoms for cancer-related malignant ascites who complete an at-home paracentesis procedure.
- Trial name
- Paracentesis (NCT07490626)
- Testing
- At-home Paracentesis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Malignant Pleural Effusion, Malignant Ascites
Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer
The purpose of this study to find out if tocilizumab can be safely infused into chest or abdominal cavities of patients with malignancy ascites (MA) or malignant pleural effusions (MPE).
- Trial name
- RIOT2 (NCT06016179)
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Malignant Ascites
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
This study is a prospective, multi-cohort Phase Ib/II clinical trial, consisting of two stages as follows: 1. Phase Ib Dose-Escalation Stage To explore the dose-limiting toxicities (DLT) of intraperitoneally administered…
- Trial name
- NCT07397819
- Testing
- liposomal irinotecan monotherapy, Liposomal Irinotecan + rmhTNF-NC, Liposomal Irinotecan + Bevacizumab
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Dong sheng Zhang
Malignant Peritoneal Effusion, Malignant Ascites
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
This is a Phase I, open-label, single-arm, dose-escalation and expansion study designed to evaluate the safety, tolerability, and preliminary antitumor activity of dual-targeting VEGFR1/PD-L1 chimeric antigen receptor (CAR)…
- Conditions
- Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises, Leptomeningeal Metastases
- Trial name
- NCT05477927
- Testing
- Dual-targeting VEGFR1/PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
STOMACH NEOPLASM, Gastric Cancer
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
To investigate efficacy and safety of lenvatinib in combination with nivolumab plus chemotherapy in gastric cancer patients with peritoneal metastasis and grade ≥ 2 ascites.
- Conditions
- STOMACH NEOPLASM, Gastric Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT07149090
- Testing
- Lenvatinib
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Asan Medical Center
Malignant Ascites
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Malignant Ascites is a common complication of malignant tumor. The objective of this study is to evaluate the safety, efficacy, and pharmacokinetic characteristics of intraperitoneal perfusion with Docetaxel Polymeric Micelles…
- Trial name
- SIM0388-101 (NCT07007988)
- Testing
- SIM0388
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Digestive System Neoplasms
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
This study is a prospective, non-randomized, dual-cohort Phase II clinical trial designed to explore the efficacy and safety of radiotherapy combined with intraperitoneal injection of Recombinant Mutant Human Tumor Necrosis…
- Trial name
- NCT07196540
- Testing
- Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors
NK521 in the Treatment of Malignant Ascites Associated With Advanced Solid Tumors
Study Population: Adult subjects aged 18-75 years with relapsed/refractory advanced solid tumors (including liver, gastric, colorectal, ovarian cancer, etc.) and malignant ascites confirmed by cytology, who have failed at least 2…
- Trial name
- NCT07561437
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumors, Malignant Pleural Effusions
WSK-IM02 in Advanced Solid Tumors With Malignant Effusions (Phase I)
This is a prospective, single-center, interventional, phase I, dose-escalation, single-arm study designed to evaluate the safety, tolerability, and preliminary efficacy of intrapleural/intraperitoneal infusion of WSK-IM02 in…
- Conditions
- Advanced Solid Tumors, Malignant Pleural Effusions, Malignant Ascites
- Trial name
- NCT07615894
- Testing
- WSK-IM02
- Where
- China
- Volunteers
- 9 people
- Sponsor
- WestVac Biopharma Co., Ltd.
Gastric Cancer, Pancreatic Cancer
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Phase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended…
- Trial name
- NCT05438459
- Testing
- GAIA-102, Pembrolizumab, Trifluridine/tipiracil hydrochloride (FTD/TPI)
- Where
- Japan
- Volunteers
- 176 people
- Sponsor
- Kyushu University
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma
- Trial name
- NCT04919629
- Testing
- Bevacizumab, Biopsy, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Roswell Park Cancer Institute
Malignant Ascites
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
- Trial name
- NCT05745233
- Testing
- Nivolumab, Pembrolizumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Hepatocellular Carcinoma (HCC), Ovarian Cancer
NK521 in the Treatment of Advanced Solid Tumors
Eligible subjects with advanced hepatocellular carcinoma and ovarian cancer will be divided into two treatment groups based on the volume of ascites.
- Conditions
- Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites
- Trial name
- NCT07657416
- Testing
- NK521 Cell Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Gynecologic Cancer
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites
The purpose of this study is to assess the safety and efficacy of NK042 for treatment of malignant ascites.
- Trial name
- NCT06415500
- Testing
- NK042
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Malignant Ascites, Colorectal Adenocarcinoma
TLR9 Immunotherapy for Peritoneal Carcinomatosis
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites.
- Conditions
- Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
- Trial name
- TIPC (NCT07658196)
- Testing
- ACM-CpG
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown University
Malignant Ascites, Apatinib
A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites
Malignant ascites is a severe complication of many types of human cancer. Animal and clinical analyses have shown that angiogenesis plays a critical role in the formation of malignant ascites.
- Trial name
- NCT03020979
- Testing
- Apatinib
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Cancer of Stomach, Adenocarcinoma, Ascites, Malignant
Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
This study is to evaluate the safety and efficacy of intraperitoneal injection of immune checkpoint inhibitor combined with zoledronic acid for the treatment of malignant ascites in gastric cancer.
- Trial name
- IPIZA (NCT06759064)
- Testing
- zoledronic acid plus Sintilimab intraperitoneal injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Qilu Hospital of Shandong University
Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC)
Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites
This prospective observational study aims to evaluate the efficacy and safety of anti-PD-1 therapy combined with systemic chemotherapy and intraperitoneal nab-paclitaxel as first-line treatment for patients with advanced gastric…
- Conditions
- Gastric Cancer Peritoneal Metastases, Gastric Cancer (GC), Ascites, Malignant
- Trial name
- NCT07855640
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Cancer Hospital
Solid Tumor, Malignant Ascites
SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites
This study is divided into two phases. Patients with recurrent or metastatic solid tumors accompanied by malignant ascites who have failed previous standard treatments are enrolled.
- Trial name
- NCT06991478
- Testing
- SK-NK injection
- Volunteers
- 10 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital